The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.
UCB Group may be late to the party when it comes to the interleukin-17 space for immune disorders but with more promising data on bimekizumab for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), the Belgian firm remains confident of getting a foothold in the market.
Bimekizumab is touted by UCB as a "key pipeline molecule" and was showcased during presentations at the European League Against...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
